HER2-positive gastric cancer accounts for a substantial proportion of advanced cases and has long been treated with HER2-targeted therapies. While trastuzumab deruxtecan has shown superior activity ...

Deep in the folds of the intestine, in microscopic pockets called crypts, a quiet surveillance system is always at work. Stem ...

A team of researchers has clarified a biological process first observed more than 50 years ago: how tissues rebuild ...

A mysterious RNA found in breast cancer led scientists to uncover an entire hidden class of cancer-specific RNAs across ...

Researchers analyzed data from 1,903 patients with stage 3 or stage 4 epithelial ovarian cancer who were enrolled in four ...

HER2-positive gastric cancer accounts for a substantial proportion of advanced cases and has long been treated with HER2-targeted therapies.

Researchers have resolved a 50-year-old scientific mystery by identifying the molecular mechanism that allows tissues to ...

A companion diagnostic test was simultaneously approved to identify eligible patients whose tumors express PD-L1 with a combined positive score of 1 or higher.

As Merck received its latest FDA nod for Keytruda in ovarian cancer, Agilent gained the green light for its accompanying test to identify patients who can best benefit from the drug.  | As Merck ...

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...

New international health data highlight clear patterns in where cancer most frequently develops. Certain organs account for a ...

The agency approved the Keytruda-based regimen after reviewing data from the KEYNOTE-B96 trial, in which Agilent's PD-L1 IHC 22C3 PharmDx test was used to stratify patients.